Kypha

Our CEO Chad Stiening will attend the upcoming Association for Diagnostics & Laboratory Medicine (formerly AACC) conference in Chicago on July 30th and 31st next week, where he will take the opportunity to connect with other global leaders in the diagnostic industry, translational medicine, lab management, and laboratory medicine. Chad would welcome the chance to meet in person, please reach out to him via his LinkedIn profile (https://lnkd.in/eevDXfXk) to arrange a meeting. Wishing all of you a successful conference in Chicago. Enjoy the show…there is no better place to learn about recent developments and the latest innovations in our industry and at Kypha! #immunediagnostics #complement #diagnostics #clinicaltrials #immunemonitoring #ADLM

At Kypha we know that complement’s impact is everywhere, but its therapeutic potential is underappreciated. For example, certain anti-cancer drugs are associated with complement-mediated side effects, including thrombotic microangiopathy (TMA) . The good news is that these are often responsive to complement inhibitors. But this only highlights why it is so important to get an accurate and timely analysis of complement markers. Being able to get a true read on complement, especially when it is delivered in real-time, has huge potential to optimize every stage of drug development and risk assessment. Find out more about how our experts see the world of complement at https://lnkd.in/e6W5mQGf . #immunediagnostics #diagnostics #complement #immunemonitoring #pointofcarediagnostics

At Kypha we know that complement’s impact is everywhere, but its therapeutic potential is underappreciated. For example, certain anti-cancer drugs are associated with complement-mediated side effects, including thrombotic microangiopathy (TMA) . The good news is that these are often responsive to complement inhibitors. But this only highlights why it is so important to get an accurate and timely analysis of complement markers. Being able to get a true read on complement, especially when it is delivered in real-time, has huge potential to optimize every stage of drug development and risk assessment. Find out more about how our experts see the world of complement at https://lnkd.in/eR7qY9mi #immunediagnostics #diagnostics #complement #immunemonitoring #pointofcarediagnostics

Mainstay vectors for gene therapy development programs are adeno-associated virus (AAV) vectors. However, their utility may be compromised by the presence of pre-existing complement-fixing antibodies….and these are found in up to 70% of the population. At Kypha our passion is complement, and we’re putting this to good use in developing state-of-the-art complement diagnostics. We are optimistic that this holds promise to help optimize gene therapy development programs to both maximize effectiveness and to guide the mitigation of complement-mediated immunogenicity. Find out more about our passion at https://lnkd.in/eNurF_TJ #immunediagnostics #diagnostics #complement #AAV #genetherapy #immunemonitoring #pointofcarediagnostics

Mainstay vectors for gene therapy development programs are adeno-associated virus (AAV) vectors. However, their utility may be compromised by the presence of pre-existing complement-fixing antibodies….and these are found in up to 70% of the population. At Kypha our passion is complement, and we’re putting this to good use in developing state-of-the-art complement diagnostics. We are optimistic that this holds promise to help optimize gene therapy development programs to both maximize effectiveness and to guide the mitigation of complement-mediated immunogenicity. Find out more about our passion at https://lnkd.in/eS8NiJGH #immunediagnostics #diagnostics #complement #AAV #genetherapy #immunemonitoring #pointofcarediagnostics

When a cytokine storm arrives, it hits hard and quickly – even within 12-36 hours. That usually isn’t enough time to get the cytokine lab results back from external specialty send-outs. And that in turn makes developing new interventions that much harder At Kypha we know that timely cytokine analysis can deliver more accurate results and give healthcare providers and drug developers the information they need to make better decision faster. Kypha’s rapid test platform is designed specifically to address these challenges, and deliver better clinical trial data.   Find out more at https://lnkd.in/eMnzviYj #diagnostics #immunediagnostics #complement #cytokinestorm #immunemonitoring

When a cytokine storm arrives, it hits hard and quickly – even within 12-36 hours. That usually isn’t enough time to get the cytokine lab results back from external specialty send-outs. And that in turn makes developing new interventions that much harder At Kypha we know that timely cytokine analysis can deliver more accurate results and give healthcare providers and drug developers the information they need to make better decision faster. Kypha’s rapid test platform is designed specifically to address these challenges, and deliver better clinical trial data. Find out more at https://lnkd.in/er7rRyi9 #diagnostics #immunediagnostics #complement #cytokinestorm #rapidtest #cytokine

Recent FDA approvals for new drugs targeting complement proteins means there has never been greater momentum than now in the development of new complement therapeutics. At Kypha we have long recognized how much potential remains untapped in the complement space. With our expertise in measuring these molecules and our purpose-built complement biomarker platform, we are well positioned to help small biotech and large pharma capitalize on this renewed focus on the complement pathway. To find out more about our complement expertise, visit https://lnkd.in/e_FJkzrA #complement #complementdiagnostics #complementtherapeutics #immunemonitoring #diagnostics #immunediagnostics

Recent FDA approvals for new drugs targeting complement proteins means there has never been greater momentum than now in the development of new complement therapeutics. At Kypha we have long recognized how much potential remains untapped in the complement space. With our expertise in measuring these molecules and our purpose-built complement biomarker platform, we are well positioned to help small biotech and large pharma capitalize on this renewed focus on the complement pathway. To find out more about our complement expertise, visit https://lnkd.in/eXvm62xD #complement #complementdiagnostics #complementtherapeutics #immunemonitoring #diagnostics #immunediagnostics

Human Stem Cell Transplant (HSCT) is an increasingly common, effective treatment for multiple hematologic/oncologic conditions. However it is a complex procedure, with important associated risks. One such risk is transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication of HSCT that causes blood clots and damage to capillary walls. These events can cause injury to organs which may lead to organ failure and death. Complement inhibition has been shown to be an effective therapeutic strategy for TA-TMA in some patients. At Kypha, our accessible and rapid complement testing will allow for monitoring is HSCT for early detection of TMA, and thereby guide early treatment and dosing decisions. Find out more about our work at https://lnkd.in/ev7qKH_u #complement #complementtesting #bonemarrowtransplant #diagnostics #immunediagnostics #precisionimmunemonitoring